Targeted agents in AML encompass small-molecular inhibitors directed against specific genomic alterations and leukemogenic pathways as well as cell surface antigens, which can be targeted by a variety of immunotherapeutic modalities. HLA, human leukocyte antigen; NK, natural killer; TCA, tricarboxylic acid; TCR, T-cell receptor.